State-of-the-art treatments in non-Hodgkin's lymphoma

Research output: Contribution to journalArticle

Abstract

The non-Hodgkin's lymphomas are a diverse group of disorders morphologically, immunologically, and clinically. It is estimated that lymphoma represents 4% of the new cancer diagnoses and 4% of the cancer deaths. Lymphoma ranks third in increases in cancer death rates since 1973. Classification schemes have been further refined reclassifying previously described entities, differentiating B and T-cell entities, and defining new entities. This review will focus on standard treatment approaches, new therapeutic approaches, and preclinical directions.

Original languageEnglish (US)
Pages (from-to)303-314
Number of pages12
JournalCancer Research Therapy and Control
Volume9
Issue number3-4
StatePublished - 1999

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Neoplasms
T-Lymphocytes
Mortality
Therapeutics
Direction compound

Keywords

  • Anti-idiotypic antibodies
  • Monoclonal antibody therapy
  • Non-Hodgkin's lymphoma
  • Non-Hodgkins lymphoma chemotherapy
  • Purine analogues
  • Vaccine therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

State-of-the-art treatments in non-Hodgkin's lymphoma. / Habermann, Thomas Matthew.

In: Cancer Research Therapy and Control, Vol. 9, No. 3-4, 1999, p. 303-314.

Research output: Contribution to journalArticle

@article{fa92cbf9ac984cd4a38b1bd52b983789,
title = "State-of-the-art treatments in non-Hodgkin's lymphoma",
abstract = "The non-Hodgkin's lymphomas are a diverse group of disorders morphologically, immunologically, and clinically. It is estimated that lymphoma represents 4{\%} of the new cancer diagnoses and 4{\%} of the cancer deaths. Lymphoma ranks third in increases in cancer death rates since 1973. Classification schemes have been further refined reclassifying previously described entities, differentiating B and T-cell entities, and defining new entities. This review will focus on standard treatment approaches, new therapeutic approaches, and preclinical directions.",
keywords = "Anti-idiotypic antibodies, Monoclonal antibody therapy, Non-Hodgkin's lymphoma, Non-Hodgkins lymphoma chemotherapy, Purine analogues, Vaccine therapy",
author = "Habermann, {Thomas Matthew}",
year = "1999",
language = "English (US)",
volume = "9",
pages = "303--314",
journal = "Cancer Research, Therapy and Control",
issn = "1064-0525",
publisher = "Harwood Academic Publishers",
number = "3-4",

}

TY - JOUR

T1 - State-of-the-art treatments in non-Hodgkin's lymphoma

AU - Habermann, Thomas Matthew

PY - 1999

Y1 - 1999

N2 - The non-Hodgkin's lymphomas are a diverse group of disorders morphologically, immunologically, and clinically. It is estimated that lymphoma represents 4% of the new cancer diagnoses and 4% of the cancer deaths. Lymphoma ranks third in increases in cancer death rates since 1973. Classification schemes have been further refined reclassifying previously described entities, differentiating B and T-cell entities, and defining new entities. This review will focus on standard treatment approaches, new therapeutic approaches, and preclinical directions.

AB - The non-Hodgkin's lymphomas are a diverse group of disorders morphologically, immunologically, and clinically. It is estimated that lymphoma represents 4% of the new cancer diagnoses and 4% of the cancer deaths. Lymphoma ranks third in increases in cancer death rates since 1973. Classification schemes have been further refined reclassifying previously described entities, differentiating B and T-cell entities, and defining new entities. This review will focus on standard treatment approaches, new therapeutic approaches, and preclinical directions.

KW - Anti-idiotypic antibodies

KW - Monoclonal antibody therapy

KW - Non-Hodgkin's lymphoma

KW - Non-Hodgkins lymphoma chemotherapy

KW - Purine analogues

KW - Vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=0032873309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032873309&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032873309

VL - 9

SP - 303

EP - 314

JO - Cancer Research, Therapy and Control

JF - Cancer Research, Therapy and Control

SN - 1064-0525

IS - 3-4

ER -